KATHERINE KREVOLIN: Open Payments
NPI 1871149153 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$954 in 46 payments from 13 companies in 2025. Trend: 2023 $1,293 · 2024 $1,290 · 2025 $954
Food & beverage: $954
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $348 |
| Janssen Biotech, Inc. | 5 | $185 |
| Ardelyx, Inc. | 5 | $112 |
| Gilead Sciences, Inc. | 4 | $73 |
| QOL Medical, LLC | 1 | $33 |
| EVOKE PHARMA, INC. | 2 | $31 |
| PFIZER INC. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: TREMFYA, VIBERZI, IBSRELA, LINZESS, SKYRIZI, Sucraid, GIMOTI, XELJANZ.
Industry payments across CT — which companies pay providers there.
